Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Virtus Health Plans to Raise About $300 Million in IPO

Virtus Health Pty Ltd., Australia’s biggest provider of fertility services, plans to sell shares in an initial public offering that may raise A$291.5 million ($298 million), according to a presentation document.

Virtus, part-owned by buyout firm Quadrant Private Equity Pty Ltd., and its investors will sell shares at A$4.92 to A$5.68 each, according to the material obtained by Bloomberg. The stock will start trading on June 14 and part of the funds will be used to pay debt, according to the document. A spokeswoman for Sydney-based Virtus declined to comment on the deal’s details.

After the sale, Virtus will have a market capitalization of as much as A$449.4 million, according to the presentation, making it the largest company to start trading on the Australian stock exchange since October. The company’s 33 fertility clinics in Victoria, Queensland and New South Wales provided 35 percent of the IVF treatment cycles performed last year in Australia, according to the presentation.

The stake held by the company’s fertility doctors will be cut in half to about 23 percent after the share sale, while Sydney-based Quadrant will reduce its 46.5 percent holding to about 10 percent and have one seat on the Virtus board, according to the presentation.

The share sale is being conducted by UBS AG and Morgan Stanley, according to the document.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.